Loading...
XNYS
MYO
Market cap56mUSD
Oct 08, Last price  
1.41USD
1D
-2.76%
1Q
28.18%
IPO
-99.36%
Name

Myomo Inc

Chart & performance

D1W1MN
XNYS:MYO chart
P/E
—
P/S
1.33
EPS
—
Div yield, %
—
Shrs. gr., 5y
65.91%
Rev. gr., 5y
40.10%
Revenues
41m
+25.73%
913,254689,6711,103,2771,558,8662,444,1043,837,7307,583,37113,856,37415,555,22919,241,15832,551,19940,928,042
Net income
-16m
L+151.85%
-3,527,796-4,482,167-3,617,022-12,097,479-10,316,739-10,713,009-11,563,911-10,372,329-10,721,022-8,147,565-6,183,729-15,573,884
CFO
-15m
L+341.09%
-2,547,045-3,334,506-3,202,670-6,153,419-9,606,310-10,341,817-9,032,896-9,547,695-10,233,542-6,172,764-3,289,904-14,511,454

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.

Key people

Paul Gudonis
Chairman of the Board, President, Chief Executive Officer · since 2017
David Henry
Chief Financial Officer · since 2019
Harry Kovelman
Chief Medical Officer · since 2020
Micah Mitchell
Chief Commercial Officer · since 2018
Thomas Kirk
Lead Independent Director · since 2016
Thomas Crowley
Independent Director · since 2012
Independent Director · since 2024
Milton Morris
Independent Director · since 2021
IPO date
Jun 12, 2017
Employees
100
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
14th Floor
One Broadway
Cambridge, MA 02142
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT